东西方肝癌的分析比较

1 on of 112008 in of n=342) n=1350) 2 4 6 8 10 12 14 16 0 2 4 6 8 10 12 14 16 in o. of +(%) M (%) F (%) %) %) 2 49 25 61 29 56 7 2 72 44 69 U 90 21 9 33 13 26 6 61 53 69 35 68 9 64 44 70 42 71 72 32 6 U 75 10 6 30 7 25 1. et 005 2. et 005 3. et 005 4. et 005 *. et 005 6. et 005 7. Mu et 005 8. et 005 in et 2001. 396,364) / 165,972) %) %) %) %) %) %) in of 46.3 10.7 (95% S/P): 95% P=34.4 7.9 (95% 80 8 16 24 32 40 48 56 64 72 0 274 241 205 161 108 67 38 12 0 at 0 276 224 179 126 78 47 25 7 2 299 303 et N 2008 4;359(4):378 (7.9 x(-) t S V V 02 17M 0%* 0%* 06 3M 14% 13% * M, 999;29:62P, 005;100:1995S vs N o. o f p a t s io n c ri t a M ov s i v m h s ) 1 - y s i v %) k er (2007) ( Sw it z t at 3 0 m g/ 4 w s 60 4. 7 41 (6 - m on t h) 59 H C C s a f o r s T ; pr lo c t c D x 5. 3 42 (6 - m on t h) Y et (2002) ( H a c t oc t id e 250 m g b f w s , t t at 3 0 m g/ 4 w s 35 1. 93 - 35 H C C s a f o r s T ; pr x , t c x 1. 97 - (2005 ) (F e) ac t oc t id e 30 m g/ 4 w s 132 6. 5 134 H C C s a f o r s T ; hi s t o c c x 7. 3 s 1998) (e) a c t oc t id e 25 0 g 28 13 56 e c 30 H C C s a f o r s c i c al or hi s t c x 4 13 P 00 mg No or S A N D O M I Z E 10.7 95% 95% P=7.9 95% 20 2 4 6 8 10 12 14 16 18 6.5 (95% 4.2 (95% S/P): 95% = 0 4 8 10 12 14 16 20 22 6 18 M, et N 008:359:378L, et 008, 509. N=226) N=602) 1 (2367 (21 % 73/8 18/28 % 85 87 S (0/1/2), % 26/69/5 54/38/8 % 35 38 % 69 51 B/C), % 4/96 17/82 of % 1 11 44 2 35 31 3 20 12 4 35 13 of % 0 21 2 26 1 , et N 008:359:378 M et 2003; 362:190730%) 50(50 if 610%) 2 -) +) , 3 4, 3 CG V (-), -) V (+) or +) ew 2 mg/ 2 mg/ 2 mg/ 2 mg/ 3 ) ) 2, ) ew -) +) . et 007 in in 2 40 1272 45 857 12 014 1050 5 0 183 4894 20 1533 40 951 0 4090 20 956 1141 22 5 X et 004;127:%) %) %) CC a CC M et 004;10() 74 et 004;10() 58in a p= to C et 006;101:91BV CC 927 or M) 1 %) 3 %) 5 %) 10 %) +C H et 2006 2(15):2524006 2 CC a CC et 002;62:3939 et 003;9:5493CV by of CC is x CC y t o ki r e c e p t o rG r o w t h t o r r e c e p t o rT o x o t he r s t r e s T P I 3 E K K k O 1P r o t e a s o m s t r e s sP S mu t a n xC e s ur ng e ne s M e t as t as i sC e c y c C e s ur e t ab o li s m d am ag eM e t ab o li s m C e c y c C e s ur e c y c P r o t e t r l at ut r ie n t r e s p o n s eP r o t e d e g r ad at e s ur C e c y c A ng e ne s M e t as t as i K 3: Ta t e d a ge n t s i n p c l i n i c a l de ve l o pm e n t: Ta t e d a ge n t s i n cl i n i c a l de ve l o pm e n t: D re gu l a t e d i n c at e ni CV y , C, L et 007;45:42. 7 in 3 v e r - e x p r e s s i o F 1 R A k t p K 3 H B V ( + ) H C V ( + )G 1 - g r o u p ( N = 1 1 ) 64% 75% 78% 8 3G 2 - g r o u p ( N = 1 7 ) 25% 42% 7 4O t h e r s ( N = 9 2 ) 9% 8% 9% 22 2327 is an CC ( W et J 005;97:265 a in C et J 005;75:513B is , C, J et 003;125:444I t %) %) M) M) M) 33 71 82 75 13 66 54 53 D et I 173. A 05 of 178) (159) 0 (325) 1277) - (421) + (181) m) R (m) 1. , et 29. 008. 2. , et . , et J 2008;25: 587. 4. , et J 2008;25: 584. I t %) 33 61 et 004: 198. P 61 09 08 be in of of I of in 1, 4, (m 008:26; #4603 ) e t t d _ 2 0 _ 2 0 0 1 K a p l a n - M e i e r p l o t o f D u r a t i o n o f S u r v i v a lP r o t o c o l : M L 1 8 4 6 9A n a l y s i s : I n t e n t t o T r e a t P o p u l a t i o nF i l t e r A p p l i e d : W H E R E I T T = Y E S 2 8 A U G 2 0 0 7 1 : 0 0 P r o g r a m : $ P R O D / c d p 1 1 9 9 9 / m l 1 8 4 6 9 / e t t d _ 2 0 . s a s / O u t p u t : $ P R O D / c d p 1 1 9 9 9 / m l 1 8 4 6 9 / r e p o r t s / e t t d _ 2 0 _ 2 0 0 1 . c g m S: (95% e t t p f s _ 2 0 _ 2 0 0 1 K a p l a n - M e i e r p l o t o f P r o g r e s s i o n F r e e S u r v i v a lP r o t o c o l : M L 1 8 4 6 9A n a l y s i s : I n t e n t t o T r e a t P o p u l a t i o nF i l t e r A p p l i e d : W H E R E I T T = Y E S 2 8 A U G 2 0 0 7 1 : 0 5 P r o g r a m : $ P R O D / c d p 1 1 9 9 9 / m l 1 8 4 6 9 / e t t p f s _ 2 0 . s a s / O u t p u t : $ P R O D / c d p 1 1 9 9 9 / m l 1 8 4 6 9 / r e p o r t s / e t t p f s _ 2 0 _ 2 0 0 1 . c g m F o r p a t i e n t s w i t h o u t a n e v e n t w i l l b e c e n s o r e d a t t h e d a t e o f l a s t a s s e s s m e n t (95% S (95% (95% H et 008: 603. 1,200 ： 1 7.5 mg,qd as as 00mg,as as 6181170 A F N . in 2. of be in of 37 on of 112008 1. , et 2007. 0, 2008. 2. , 2008. 196,298 226,787 230,555 200,774 314,256 330,963 529,283 559,094 711,128 782,647 1,066,543 1,167,020 1,301,867 1,549,121 0 200,00